A case report of secondary B-cell acute lymphoblastic leukemia treated with a combination of FLT3 inhibitor and decitabine

• Published in: Frontiers in Oncology
• Main Authors: Mengci Hu, Wenzhe Li, Pan Li, Jie Tan, Ya Wang
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2024-04-01
• Subjects: diffuse large B-cell lymphoma; acute lymphoblastic leukemia; secondary acute lymphoblastic leukemia; FLT3; myelodysplastic syndrome
• Online Access: https://www.frontiersin.org/articles/10.3389/fonc.2024.1329279/full
• ISSN: 2234-943X

Secondary acute lymphoblastic leukemia (s-ALL) refers to acute lymphoblastic leukemia that occurs after a previous malignant tumor, including therapy-related acute lymphoblastic leukemia (t-ALL) and prior malignant tumor acute lymphoblastic leukemia (pm-ALL). We report a case of a 51-year-old female patient who developed acute lymphoblastic leukemia 14 years after being diagnosed with diffuse large B-cell lymphoma (DLBCL). The patient was unresponsive to conventional chemotherapy for acute lymphoblastic leukemia (ALL) and achieved remission with a combination of sorafenib and decitabine based on the molecular biology characteristics of her B-ALL.